{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:20:30Z","timestamp":1776763230029,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002562","name":"Sunchon National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00228-025-03901-y","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T17:34:32Z","timestamp":1754933672000},"page":"1541-1554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unraveling the impact of renal impairment and renal replacement therapy modalities on fluconazole pharmacokinetics"],"prefix":"10.1007","volume":"81","author":[{"given":"Ji-Hun","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Hwan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"5","key":"3901_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/jac\/35.5.641","volume":"35","author":"M Ruhnke","year":"1995","unstructured":"Ruhnke M, Yeates R, Pfaff G, Sarnow E, Hartmann A, Trautmann M (1995) Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. J Antimicrob Chemother 35(5):641\u2013647. https:\/\/doi.org\/10.1093\/jac\/35.5.641","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"3901_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1358\/dot.2015.51.12.2421058","volume":"51","author":"L Peyton","year":"2015","unstructured":"Peyton L, Gallagher S, Hashemzadeh M (2015) Triazole antifungals: a review. Drugs Today (Barc) 51(12):705\u2013718. https:\/\/doi.org\/10.1358\/dot.2015.51.12.2421058","journal-title":"Drugs Today (Barc)"},{"issue":"Supplement_3","key":"3901_CR3","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","volume":"12","author":"KW Brammer","year":"1990","unstructured":"Brammer KW, Farrow PR, Faulkner JK (1990) Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12(Supplement_3):S318\u2013S326. https:\/\/doi.org\/10.1093\/clinids\/12.Supplement_3.S318","journal-title":"Rev Infect Dis"},{"issue":"10","key":"3901_CR4","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1007\/s00134-003-1980-z","volume":"29","author":"K Yagasaki","year":"2003","unstructured":"Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hirano T, Iseki K (2003) Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 29(10):1844\u20131848. https:\/\/doi.org\/10.1007\/s00134-003-1980-z","journal-title":"Intensive Care Med"},{"key":"3901_CR5","doi-asserted-by":"publisher","unstructured":"Muilwijk EW, Lange DWd, Schouten JA, Wasmann RE, Heine Rt, Burger DM, Colbers A, Haas PJ, Verweij PE, Pickkers P, Br\u00fcggemann RJ (2020) Suboptimal dosing of fluconazole in critically Ill patients: Time To rethink dosing. Antimicrob Agents Chemother 64 (10): 10.1128\/aac.00984-00920. https:\/\/doi.org\/10.1128\/aac.00984-20","DOI":"10.1128\/aac.00984-20"},{"issue":"1\u20132","key":"3901_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1439-0507.1999.00269.x","volume":"42","author":"L Pittrow","year":"1999","unstructured":"Pittrow L, Penk A (1999) Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD). Mycoses 42(1\u20132):17\u201319. https:\/\/doi.org\/10.1046\/j.1439-0507.1999.00269.x","journal-title":"Mycoses"},{"issue":"9","key":"3901_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s002280000216","volume":"56","author":"E Muhl","year":"2000","unstructured":"Muhl E, Martens T, Iven H, Rob P, Bruch HP (2000) Influence of continuous veno\u2013venous haemodiafiltration and continuous veno\u2013venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 56(9):671\u2013678. https:\/\/doi.org\/10.1007\/s002280000216","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3901_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0149-2918(97)80056-2","volume":"19","author":"S-f Wong","year":"1997","unstructured":"Wong S-f, Leung MP, Chan M-Y (1997) Pharmacokinetics of fluconazole in children requiring peritoneal dialysis. Clin Ther 19(5):1039\u20131047. https:\/\/doi.org\/10.1016\/S0149-2918(97)80056-2","journal-title":"Clin Ther"},{"issue":"1","key":"3901_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00007691-200102000-00002","volume":"23","author":"S Kishino","year":"2001","unstructured":"Kishino S, Koshinami Y, Hosoi T, Suda N, Takekuma Y, Gandoh S, Furukawa H, Todo S, Miyazaki K (2001) Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration. Ther Drug Monit 23(1):4\u20138","journal-title":"Ther Drug Monit"},{"issue":"3","key":"3901_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00198243","volume":"73","author":"J Scholz","year":"1995","unstructured":"Scholz J, Steinfath M, H\u00f6ver S, Bause H, Schulz M (1995) Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient. J Mol Med 73(3):145\u2013147. https:\/\/doi.org\/10.1007\/BF00198243","journal-title":"J Mol Med"},{"issue":"12","key":"3901_CR11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1345\/aph.18152","volume":"32","author":"NV Dahl","year":"1998","unstructured":"Dahl NV, Foote EF, Searson KM, Fein JL, Kapoian T, Steward CA, Sherman RA (1998) Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis. Ann Pharmacother 32(12):1284\u20131289. https:\/\/doi.org\/10.1345\/aph.18152","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3901_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000238967","volume":"39","author":"S Ripa","year":"1993","unstructured":"Ripa S, Ferrante L, Prenna M (1993) Pharmacokinetics of fluconazole in normal volunteers. Chemotherapy 39(1):6\u201312. https:\/\/doi.org\/10.1159\/000238967","journal-title":"Chemotherapy"},{"issue":"1","key":"3901_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s001340000771","volume":"27","author":"SLCE Buijk","year":"2001","unstructured":"Buijk SLCE, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA (2001) Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med 27(1):115\u2013121. https:\/\/doi.org\/10.1007\/s001340000771","journal-title":"Intensive Care Med"},{"key":"3901_CR14","doi-asserted-by":"publisher","unstructured":"Zhou W, Nightingale C, Davis G, Nicolau D (2001) Absolute bioavailability of fluconazole suspension in intensive care unit patients.https:\/\/doi.org\/10.1300\/J100v05n01_02","DOI":"10.1300\/J100v05n01_02"},{"issue":"2","key":"3901_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/jac\/36.2.395","volume":"36","author":"DP Nicolau","year":"1995","unstructured":"Nicolau DP, Crowe H, Nightingale CH, Qutnatiliani R (1995) Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 36(2):395\u2013401. https:\/\/doi.org\/10.1093\/jac\/36.2.395","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"3901_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ndt\/gfi284","volume":"21","author":"R Bergner","year":"2005","unstructured":"Bergner R, Hoffmann M, Riedel K-D, Mikus G, Henrich DM, Haefeli WE, Uppenkamp M, Walter-Sack I (2005) Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 21(4):1019\u20131023. https:\/\/doi.org\/10.1093\/ndt\/gfi284","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3901_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jac\/40.5.695","volume":"40","author":"M Valtonen","year":"1997","unstructured":"Valtonen M, Tiula E, Neuvonen PJ (1997) Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 40(5):695\u2013700. https:\/\/doi.org\/10.1093\/jac\/40.5.695","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"3901_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2125.1990.tb03623.x","volume":"29","author":"S Toon","year":"1990","unstructured":"Toon S, Ross C, Gokal R, Rowland M (1990) An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 29(2):221\u2013226. https:\/\/doi.org\/10.1111\/j.1365-2125.1990.tb03623.x","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"3901_CR19","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/cid\/ciu657","volume":"59","author":"KCM van der Elst","year":"2014","unstructured":"van der Elst KCM, Pereboom M, van den Heuvel ER, Kosterink JGW, Sch\u00f6lvinck EH, Alffenaar J-WC (2014) Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically Ill children. Clin Infect Dis 59(11):1527\u20131533. https:\/\/doi.org\/10.1093\/cid\/ciu657","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3901_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00005373-199509000-00008","volume":"39","author":"AS Rosemurgy","year":"1995","unstructured":"Rosemurgy AS, Markowsky S, Goode SE, Plastino K, Kearney RE (1995) Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration. J Trauma Acute Care Surg 39(3):445\u2013447","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"3901_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40780-018-0103-5","volume":"4","author":"K Murakoso","year":"2018","unstructured":"Murakoso K, Minagawa R, Echizen H (2018) Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis. J Pharm Health Care Sci 4(1):5. https:\/\/doi.org\/10.1186\/s40780-018-0103-5","journal-title":"J Pharm Health Care Sci"},{"issue":"6","key":"3901_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P (2017) Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45(6):737\u2013779. https:\/\/doi.org\/10.1007\/s15010-017-1042-z","journal-title":"Infection"},{"issue":"2","key":"3901_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12281-010-0015-9","volume":"4","author":"JM Cota","year":"2010","unstructured":"Cota JM, Burgess DS (2010) Antifungal dose adjustment in renal and hepatic dysfunction: pharmacokinetic and pharmacodynamic considerations. Curr Fungal Infect Rep 4(2):120\u2013128. https:\/\/doi.org\/10.1007\/s12281-010-0015-9","journal-title":"Curr Fungal Infect Rep"},{"issue":"2","key":"3901_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1681\/asn.v62242","volume":"6","author":"T Berl","year":"1995","unstructured":"Berl T, Wilner KD, Gardner M, Hansen RA, Farmer B, Baris BA, Henrich WL (1995) Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 6(2):242\u2013247. https:\/\/doi.org\/10.1681\/asn.v62242","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3901_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/BF00265934","volume":"42","author":"S Oono","year":"1992","unstructured":"Oono S, Tabei K, Tetsuka T, Asano Y (1992) The pharmacokinetics of fluconazole during haemodialysis in uraemic patients. Eur J Clin Pharmacol 42(6):667\u2013669. https:\/\/doi.org\/10.1007\/BF00265934","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03901-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:22:08Z","timestamp":1759994528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03901-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3901"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03901-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}